On August 11, 2026 SL Science Holding Limited ("SL Science" or the "Company") (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, reported the publication of a peer-reviewed article in Biomedicines. Co-authored by SL Science leadership and clinical researchers from Taipei Medical University, the article outlines a rigorous development framework for γδ T cell therapy in glioblastoma –a common and aggressive primary brain cancer in adults. Beyond reviewing existing literature, the paper outlines the specific clinical trial designs, biological measurements, and testing conditions required to rigorously evaluate γδ T cell therapies in future human trials.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Strategic Impact on SL Science’s Business and Research
The publication serves as an industry roadmap while validating SL Science’s overarching business strategy and research direction. Glioblastoma remains notoriously difficult to treat because tumors rapidly mutate and evade traditional therapies aimed at a single target. In contrast, γδ T cells recognize cancer through universal stress signals rather than single antigens, target the stem-like cells responsible for tumor recurrence, and carry a low risk of graft-versus-host disease. This unique biology makes them suited for allogeneic, "off-the-shelf" manufacturing from healthy donors and repeated localized delivery directly to the brain, which is a model that directly mirrors SL Science’s FDA Drug Master File-backed platform. By publishing this framework alongside clinical researchers, SL Science establishes a clear standard of evidence for its own pipeline, supporting the design of future clinical programs to evaluate whether cells successfully reach, persist, and function within the tumor.
Translating Lab Science into Clinical Reality
To bridge the gap between promising laboratory data and actual patient outcomes, the framework outlines key operational shifts for clinical research. The authors stress that early-phase trials must embed quantitative cell-tracking and serial pharmacodynamic sampling to determine whether a treatment outcome is driven by cellular delivery, persistence, or functional exhaustion. Furthermore, cellular potency must be tested under realistic, low-oxygen and low-glucose tumor conditions rather than ideal laboratory environments. The article also supports direct, repeated delivery to the tumor cavity as a practical method to overcome the blood-brain barrier, while cautioning that trial endpoints should focus on verifiable biological activity before attempting to prove overall survival benefits in small, early-stage cohorts.
Management Commentary
"Glioblastoma has repeatedly defeated therapies that looked convincing in preclinical models. The clear lesson is that progress depends on rigorous evidence generation in humans, not further laboratory speculation," said Mr. William Wang, Chairman and Chief Executive Officer of SL Science. "This publication defines what we believe the next phase of development must look like: clinical trials designed from day one to show whether these cells reach the tumor, remain viable, and execute their therapeutic function. Translating this science into actionable clinical proof is our core focus, and our technology is advancing and evolving alongside new clinical discoveries. We intend our own programs to meet the exact standard we have set out here."
Clinical Context and Regulatory Disclosures
The article maintains a transparent assessment of current clinical evidence, noting that γδ T cell therapy in glioblastoma remains investigational. The publication represents an independent narrative review co-authored by company leadership in their personal scientific capacities; it received no external funding, was conducted independently of any commercial product, and does not evaluate or endorse any specific proprietary SL Science candidate.
(Press release, SL Science, AUG 11, 2026, View Source [SID1234669975])